期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2010-2012年SCI收录我国肿瘤学论文的文献计量分析 被引量：8

A bibliometric analysis of oncology papers published by Chinese authors covered in SCI from 2010 to 2012
下载PDF
导出
摘要 对2010-2012年SCIE收录我国肿瘤学论文进行文献计量分析,以了解我国肿瘤学论文存在的问题及今后努力的方向。 The oncology papers published by Chinese authors covered in SCI from 2010 to 2012 were analyzed by bibliometrics in order to find their related problems and solutions.
作者 郑津津 张惠荣 井深 姜珊
机构地区 天津医科大学附属肿瘤医院图书馆
出处 《中华医学图书情报杂志》 CAS 2012年第12期64-66,71,共4页 Chinese Journal of Medical Library and Information Science
关键词 SCI 肿瘤学科 影响因子 文献计量学 SCI Oncology Impact factor Bibliometrics
分类号 G250.252 [文化科学—图书馆学] R73 [医药卫生—肿瘤]
  • 相关文献

参考文献6

二级参考文献31

  • 1戚连忠.我国林业机构论文SCI收录情况统计分析[J].农业图书情报学刊,2004,16(8):91-95. 被引量：5
  • 2曲保丽.同济医学院被SCI收录论文统计分析[J].医学信息学杂志,2006,27(2):104-107. 被引量：5
  • 3陈建青,杜云祥,湛佑祥.中国高影响力医学期刊论文计量报告.北京:中国科学技术出版社,2006:2.
  • 4广东省卫生厅.广东省卫生厅正式公布18个医院重点专科[EB/OL].2003-03-20[2007-10-22].http://www.medste.gd.cn.
  • 5Borner K, Chen C M, Boyack K W. Visualizing Knowledge Domains[ J]. Annual Review of Information Science & Technology, 2003:37(5) :179 -255.
  • 6Rip A. Qualitative Conditions of Scientometrics : The New Challenges[J]. Scientometrics, 1997,38 ( 1 ) :7 - 26.
  • 7Borner K. Mapping the Structure and Evolution of Science[ R]. Bethesda: Symposium on Knowledge Discovery and Knowledge Management Tools at NIH Natcher Conference Center,2006.
  • 8Boyack K W, Borner K, Klavans R. Mapping the Structure and Evolution of Chemistry Research [ J ]. Scientometrics, 2009, 79 (1) : 45 -60.
  • 9Leydesdorff L, Rafols I. A Global Map of Science Based on the ISI Subject Categories[ J]. Journal of the American Society for Information Science and Technology, 2009,60 ( 2 ) : 348 - 362.
  • 10Chen Y W, Yang Z P, Fang S. A Comparative Study on the Biotechnology Patents of CAS [ C ]. In : Proceedings of the 12th International Conference on Scientometrics and lnformetrics. Rio De Janeiro,Brasil: ISSI, 2009.

共引文献24

同被引文献50

  • 1International Agency for Research on Cancer , World Health Organization. All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012[EB/ OL]. (2013-12-12)[ 2014-10-21]. http://globocan.iarc.fr/Pages/fact_ sheets_cancer.aspx.
  • 2Qin H, Lerman B, Sakamaki I, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice[J]. Nat Med, 2014, 20(6): 676-681.
  • 3Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausalhormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
  • 4Thirumurthi U, Sben J, Xia W, et al. MDM2-mediated degradation of SIRT6 pbospborylated by AKTI promotes tumorigenesis and lrasluzumab resistance in breast cancer[J].Sci Signal, 2014, 7(336): ra7l.
  • 5Ying H, Kimmelman A C, Lyssiotis C A, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabo1ism[J].Cell, 2012, 149(3): 656-670.
  • 6Sbao D D, Xue W, Krall E B, et al. KRAS and YAPI converge to regulate EMT and tumor survival[J].ca. 2014,158 (1): 171-184.
  • 7Stupp R, Hcgi M E, Mason W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a rancIomised phase m study: 5-year analysis oftbe EORTC-NCIC trial[J].Loncet Oncol, 2009, 10(5): 459-466.
  • 8Cbow E, van der Linden Y M, Roos D, et al. Single versus multiple fractions of repeat radiationfor painful bone metastases: a randomised, controlled, non-inferiority triaI[J].Lancet Oncol, 2014,15(2): 164-171.
  • 9Venna S, Mile D, Gianni L, et al. Trastuzumab emtansine for HER2- positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783- 1791.
  • 10Saeki M, Egusa H, Kamano Y, et al. Exosome-bound WD repeat protein Monad inhibits breast cancer cell invasion by degrading amphiregulin mRNA[J]. PLoS, 2013, 8(7): e67326.

引证文献8

二级引证文献18

中华医学图书情报杂志
2012年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部